JP2004527450A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527450A5
JP2004527450A5 JP2001564788A JP2001564788A JP2004527450A5 JP 2004527450 A5 JP2004527450 A5 JP 2004527450A5 JP 2001564788 A JP2001564788 A JP 2001564788A JP 2001564788 A JP2001564788 A JP 2001564788A JP 2004527450 A5 JP2004527450 A5 JP 2004527450A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001564788A
Other languages
Japanese (ja)
Other versions
JP2004527450A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US09/731,375 external-priority patent/US8153414B2/en
Publication of JP2004527450A publication Critical patent/JP2004527450A/ja
Publication of JP2004527450A5 publication Critical patent/JP2004527450A5/ja
Pending legal-status Critical Current

Links

JP2001564788A 2000-04-06 2000-12-06 微生物送達システム Pending JP2004527450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19503500P 2000-04-06 2000-04-06
US09/731,375 US8153414B2 (en) 2000-04-06 2000-12-06 Microbial delivery system
PCT/US2000/033121 WO2001066136A2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009166724A Division JP2009242427A (ja) 2000-04-06 2009-07-15 微生物送達システム

Publications (2)

Publication Number Publication Date
JP2004527450A JP2004527450A (ja) 2004-09-09
JP2004527450A5 true JP2004527450A5 (enExample) 2005-12-22

Family

ID=26890647

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001564788A Pending JP2004527450A (ja) 2000-04-06 2000-12-06 微生物送達システム
JP2009166724A Pending JP2009242427A (ja) 2000-04-06 2009-07-15 微生物送達システム
JP2012154555A Pending JP2012207032A (ja) 2000-04-06 2012-07-10 微生物送達システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009166724A Pending JP2009242427A (ja) 2000-04-06 2009-07-15 微生物送達システム
JP2012154555A Pending JP2012207032A (ja) 2000-04-06 2012-07-10 微生物送達システム

Country Status (11)

Country Link
US (6) US8153414B2 (enExample)
EP (1) EP1272213B1 (enExample)
JP (3) JP2004527450A (enExample)
AT (1) ATE319475T1 (enExample)
AU (2) AU2001219510B2 (enExample)
CA (1) CA2403292C (enExample)
CY (1) CY1105216T1 (enExample)
DE (1) DE60026584T2 (enExample)
DK (1) DK1272213T3 (enExample)
ES (1) ES2260078T3 (enExample)
WO (1) WO2001066136A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
US8153414B2 (en) * 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
CA2405424A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20070231796A1 (en) * 2003-09-17 2007-10-04 The Regents Of The University Of California Sensor and method for detection of a target substance
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
JP2008516610A (ja) * 2004-10-18 2008-05-22 グローブイミューン,インコーポレイテッド 酵母を用いた慢性c型肝炎感染の治療
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2676783C (en) 2007-02-02 2016-04-05 Globeimmune, Inc. Improved methods for producing yeast-based vaccines
BRPI0809247A2 (pt) * 2007-03-19 2014-09-09 Globeimmune Inc Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
ES2585407T3 (es) 2008-02-01 2016-10-05 Murdoch Childrens Research Institute Un método para inducir tolerancia a un alérgeno
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
CN102639702A (zh) * 2009-07-13 2012-08-15 疫苗基因集团 使用可食用的微生物制造及施用的口服疫苗
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP3266464A3 (en) 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
KR102046449B1 (ko) 2011-03-17 2019-11-19 글로브이뮨 효모-브라큐리 면역요법 조성물
EA030381B1 (ru) 2011-06-14 2018-07-31 Глоубиммьюн, Инк. Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
US20130216589A1 (en) * 2012-02-17 2013-08-22 Rich Content Biotech INC. Oral vaccine for aquatic animals
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US9653272B2 (en) 2012-06-26 2017-05-16 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3482771B1 (en) 2013-03-14 2023-01-18 Société des Produits Nestlé S.A. Manufacture of peanut formulations for oral desensitization
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
JP6452718B2 (ja) 2014-04-03 2019-01-16 ジェニスフィア・エルエルシー 食物アレルギーを検出するためのペプチド、試薬及び方法
CN113419058B (zh) 2014-04-11 2025-04-01 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11547662B2 (en) 2017-10-25 2023-01-10 Allero Therapeutics B.V. Treatment of immune diseases by administration of antigen-specific formulations
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
EP3793576A4 (en) 2018-05-15 2022-04-06 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
EP3897681A4 (en) 2018-12-20 2022-10-26 Société des Produits Nestlé S.A. DOSING SCHEDULE APPLICABLE FOR ORAL IMMUNOTHERAPY AGAINST PEANUT FOR MISSED DOSES
JP7574222B2 (ja) 2019-05-10 2024-10-28 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ピーナツアレルギー患者の生活の質を改善するための方法
EP4100057A4 (en) * 2020-02-06 2024-02-21 Allergenis LLC TESTS FOR DETECTING PEANUT ALLERGIES
WO2025212530A1 (en) 2024-04-01 2025-10-09 N-Fold Llc Nanoparticle manufacturing

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588799A (en) * 1897-08-24 Mechanism
US3097141A (en) * 1959-02-26 1963-07-09 Kidwell Elizabeth N Wilcox Immunological method
SE337223B (enExample) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4338297A (en) 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
AR231590A1 (es) 1981-04-29 1984-12-28 Ciba Geigy Ag Dispositivo de analisis inmunologico y procedimiento para obtenerlo
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
SE8205908D0 (sv) 1982-10-18 1982-10-18 Pharmacia Diagnostics Ab Sett att bilda polymerskikt
US4849337A (en) 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
CA1260828A (en) * 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4579840A (en) 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4696915A (en) 1984-05-25 1987-09-29 Hoffmann-La Roche Inc. Parathymosin alpha
US5026545A (en) 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4658022A (en) * 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5843710A (en) 1987-07-07 1998-12-01 Biotech Australia Pty. Limited And Csiro Vaccines against animal parasitic nematodes
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AT393137B (de) 1988-10-14 1991-08-26 Biomay Biotech Prod Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
JP2787162B2 (ja) 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US5328991A (en) * 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
ES2174822T3 (es) 1989-11-03 2002-11-16 Immulogic Pharma Corp Una proteina felina reactiva con celulas t humanas (trfp) aislada de polvo domestico y usos para la misma.
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
JP3307636B2 (ja) 1990-01-31 2002-07-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ 自己免疫疾患のためのアッセイおよび治療
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5091318A (en) 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
AU657917B2 (en) 1990-08-08 1995-03-30 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergens of alder pollen and applications thereof
AT401180B (de) 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
JPH05502589A (ja) 1990-08-13 1993-05-13 バイオメイ バイオテクニック プロダクションズ ウント ヘンデルスゲゼルシャフト エム.ベー.ハー. アレルギー疾患の診断および治療用のカバ花粉アレルゲンp14
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
EP0504410B1 (en) 1990-09-17 1999-01-13 Mitsui Chemicals, Inc. Polycarbonate, use thereof, production thereof, and purification thereof
US5599537A (en) 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JP3156237B2 (ja) 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトIgE モノクローナル抗体
EP0628083A1 (en) * 1992-02-27 1994-12-14 Microbial Technics Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
DE69305313T3 (de) 1992-12-22 2001-06-21 The University Of Cincinnati, Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
CA2152818A1 (en) 1992-12-31 1994-07-21 Jay P. Morgenstern Allergenic proteins and peptides from dog dander and uses therefor
JPH08509956A (ja) 1993-02-12 1996-10-22 マヨ ファウンデーション フォー メディカル エデュケイション アンド リサーチ 凝縮相微小球体組成物および方法
AU683454B2 (en) 1993-02-22 1997-11-13 General Hospital Corporation, The Heterologous antigens in live cell vaccine strains
JP3451572B2 (ja) 1993-03-04 2003-09-29 アサヒビール株式会社 改変したダニ主要アレルゲン及びその製造方法
US5710126A (en) 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
FI954269L (fi) 1993-03-12 1995-09-12 Immunologic Pharma Corp Raiheinäsiitepölyallergeenin T-soluepitoopit
US6849427B1 (en) 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3350794B2 (ja) 1993-09-29 2002-11-25 アサヒビール株式会社 改変したダニ主要アレルゲン
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5449669A (en) 1993-11-10 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp
US5731157A (en) 1993-12-30 1998-03-24 The Procter And Gamble Company Two-site allergen immunoassay
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07285875A (ja) 1994-04-19 1995-10-31 Mineo Hayazaki ノミアレルゲンの製造方法および該方法により製造されるノミアレルゲン
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
SE9402089D0 (sv) 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69633857T2 (de) * 1995-03-28 2005-12-01 Asahi Breweries Ltd. Modifiziertes Allergen N
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
CA2241918C (en) * 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
SE9604815D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
WO1998044096A2 (en) * 1997-03-28 1998-10-08 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE69738124T2 (de) 1997-05-08 2008-06-12 Amarnath Maitra Verfahren zur Herstellung von hochmonodisperser, Polymeren, hydrophiler Nanopartikel
DE19729327C1 (de) * 1997-07-09 1998-10-29 Wieland Electric Gmbh Schutzleiterklemme
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
CA2319437C (en) * 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions
JP2002510644A (ja) * 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
CA2333750A1 (en) * 1998-06-23 1999-12-29 Dale T. Umetsu Adjuvant therapy
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
JP2000210050A (ja) * 1998-11-20 2000-08-02 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US8153414B2 (en) * 2000-04-06 2012-04-10 Allertein Therapeutics, Llc Microbial delivery system
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
ATE347376T1 (de) * 2000-12-28 2006-12-15 Biomay Prod & Handel Behandlung von allergien
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
BE2017C009I2 (enExample)
BE2015C062I2 (enExample)
BE2014C035I2 (enExample)
BE2014C019I2 (enExample)
BE2010C019I2 (enExample)
BE2010C018I2 (enExample)
AU2000236815A8 (enExample)
AR028236A3 (enExample)
BE2010C040I2 (enExample)
BR122012015772A2 (enExample)
CN3137473S (enExample)
CN3141860S (enExample)
AU2000274567A8 (enExample)
AU2000273097A8 (enExample)
AU2000270757A8 (enExample)
AU2000240338A8 (enExample)
CN3147715S (enExample)
CN3135387S (enExample)
CN3135513S (enExample)
CN3135930S (enExample)
CN3136653S (enExample)
CN3137238S (enExample)
CN3137256S (enExample)
CN3145472S (enExample)
CN3137476S (enExample)